Your browser doesn't support javascript.
loading
Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome.
Ko, Dennis T; Krumholz, Harlan M; Tu, Jack V; Austin, Peter C; Stukel, Therese A; Koh, Maria; Chong, Alice; de Melo, Jose Francisco; Jackevicius, Cynthia A.
Afiliación
  • Ko DT; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
  • Krumholz HM; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
  • Tu JV; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
  • Austin PC; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
  • Stukel TA; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
  • Koh M; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
  • Chong A; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
  • de Melo JF; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
  • Jackevicius CA; From the Schulich Heart Centre, Sunnybrook Health Sciences Centre (D.T.K., J.V.T.) and Institute of Health Policy, Management and Evaluation (D.T.K., J.V.T., P.C.A., T.A.S., C.A.J.), University of Toronto, Canada; Institute for Clinical Evaluative Sciences, Toronto, Canada (D.T.K., J.V.T., P.C.A., T
Circ Cardiovasc Qual Outcomes ; 11(3): e004194, 2018 03.
Article en En | MEDLINE | ID: mdl-29535091
BACKGROUND: Clopidogrel is one of the most commonly prescribed medications because of its ability to improve clinical outcomes for a broad range of cardiovascular conditions. After patent protection expired for Plavix in 2012, many healthcare systems adopted generic clopidogrel as a strategy to reduce healthcare costs. METHODS AND RESULTS: We conducted a population-based observational study to determine whether generic clopidogrel was noninferior to Plavix. Patients who were hospitalized with an acute coronary syndrome (ACS) from 2009 to 2014 in Ontario, Canada, >65 years, survived ≥7 days after discharge, were eligible for inclusion. The primary outcome was a composite of death and recurrent ACS at 1 year. The noninferiority margin was prespecified at a relative hazard difference of 10%. Inverse propensity of treatment weighting of the propensity score was used to account for differences in baseline characteristics between the treatment groups. The effect of clopidogrel on the hazard of clinical outcomes was estimated using a Cox proportional hazards model within the propensity-weighted cohort using Plavix as a reference. Our study included 24 530 patients with ACS, 12 643 were prescribed Plavix and 11 887 were prescribed generic clopidogrel at hospital discharge. The mean age was 77 years, 57% were men, and 21% had an ST-segment-elevation myocardial infarction. At 1 year, 17.6% of patients prescribed Plavix and 17.9% of patients prescribed clopidogrel experienced the primary outcome (hazard ratio, 1.02; 95% confidence interval, 0.96-1.08; P=0.005 for noninferiority). No significant differences between rates of death, all-cause readmission, ACS, stroke or transient ischemic attack, or bleeding were observed. CONCLUSIONS: Generic clopidogrel was noninferior to Plavix with respect to the composite end point of death and recurrent hospitalization for ACS at 1 year among adults >65 years after an ACS hospitalization. Our findings support generic clopidogrel in ACS, which could lead to substantial healthcare cost savings.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Admisión del Paciente / Inhibidores de Agregación Plaquetaria / Medicamentos Genéricos / Síndrome Coronario Agudo / Antagonistas del Receptor Purinérgico P2Y / Clopidogrel Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Circ Cardiovasc Qual Outcomes Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Admisión del Paciente / Inhibidores de Agregación Plaquetaria / Medicamentos Genéricos / Síndrome Coronario Agudo / Antagonistas del Receptor Purinérgico P2Y / Clopidogrel Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Circ Cardiovasc Qual Outcomes Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos